← All claims

Diets · Metabolic & Cardiometabolic

Does lowering cholesterol more cut heart risk more?

The claim, precisely: magnitude of LDL reduction correlates with cardiovascular disease

Refuted Diets 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score -0.73

No — across trials the link is weak, but this doesn't mean cholesterol is harmless.

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

0 support 4 contradict 0 tested null 1 mixed · 3 sources, 2 independent groups

What the evidence shows

At the trial level, the MAGNITUDE of LDL lowering is a weak predictor of the size of a statin's cardiovascular benefit (Byrne 2022; Liaigre 2025, R^2~0). Norwitz uses this to attack LDL. The honest nuance: this is about dose-response SURROGACY across heterogeneous trials - it does NOT overturn LDL CAUSALITY, which Mendelian randomization and per-mmol CTT analyses support. So: low confidence in the

The evidence (5)

SourceGradeStanceQualityFinding
Liaigre L, et al.
2025 · Eur Heart J Cardiovasc Pharmacother
meta-analysis contradicts low Umbrella MA 20 RCTs/194,686: trial-level R^2 for LDL vs CV outcomes ~0-0.1
Li
2021 · Eur J Clin Invest
meta-analysis mixed high Umbrella review: many drug-outcome associations weak; anchors that magnitude-benefit links are often overstated
Byrne P, et al.
2022 · JAMA Intern Med
meta-analysis contradicts moderate [FT-verified] Byrne2022: weak LDL-MI corr, R2=0 for mortality/stroke; benefit not strongly LDL-mediated at trial level
Byrne P, et al.
2022 · JAMA Intern Med
meta-analysis contradicts moderate MA 21 RCTs: weak/inconsistent association between LDL-lowering magnitude and absolute outcome reductions
Liaigre L, et al.
2025 · Eur Heart J Cardiovasc Pharmacother
meta-analysis contradicts high [FT-verified] Liaigre2025 umbrella 20RCTs/194k: trial-level R2 0-0.1 LDL (valid needs>=0.65); lit discrepant; individual surrogacy holds

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.